A miR-200b/200c/429-Binding Site Polymorphism in the 3′ Untranslated Region of the AP-2α Gene Is Associated with Cisplatin Resistance
Open Access
- 14 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12), e29043
- https://doi.org/10.1371/journal.pone.0029043
Abstract
The transcription factor AP-2α functions as a tumor suppressor by regulating various genes that are involved in cell proliferation and apoptosis. Chemotherapeutic drugs including cisplatin induce post-transcriptionally endogenous AP-2α, which contributes to chemosensitivity by enhancing therapy-induced apoptosis. microRNAs (miRNAs) miR-200b, miR-200c and miR-429 (miR-200b/200c/429) are up-regulated in endometrial and esophageal cancers, and their overexpression correlates with resistance to cisplatin treatment. Using computational programs, we predicted that the 3′ untranslated region (UTR) of AP-2α gene contains a potential miRNA response element (MRE) for the miR-200b/200c/429 family, and the single nucleotide polymorphism (SNP) site rs1045385 (A or C allele) resided within the predicted MRE. Luciferase assays and Western blot analysis demonstrated that the miR-200b/200c/429 family recognized the MRE in the 3′ UTR of AP-2α gene and negatively regulated the expression of endogenous AP-2α proteins. SNP rs1045385 A>C variation enhanced AP-2α expression by disrupting the binding of the miR-200b/200c/429 family to the 3′ UTR of AP-2α. The effects of the two polymorphic variants on cisplatin sensitivity were determined by clonogenic assay. The overexpression of AP-2α with mutant 3′ UTR (C allele) in the endometrial cancer cell line HEC-1A, which has high levels of endogenous miR-200b/200c/429 and low levels of AP-2α protein, significantly increased cisplatin sensitivity, but overexpression of A allele of AP-2α has no significant effects, compared with mock transfection. We concluded that miR-200b/200c/429 induced cisplatin resistance by repressing AP-2α expression in endometrial cancer cells. The SNP (rs1045385) A>C variation decreased the binding of miR-200b/200c/429 to the 3′ UTR of AP-2α, which upregulated AP-2α protein expression and increased cisplatin sensitivity. Our results suggest that SNP (rs1045385) may be a potential prognostic marker for cisplatin treatment.Keywords
This publication has 31 references indexed in Scilit:
- MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory PathwaysGenes & Cancer, 2010
- Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor SusceptibilityCancer Research, 2010
- A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer PathogenesisCancer Research, 2009
- Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpressionBritish Journal of Cancer, 2009
- DIANA-microT web server: elucidating microRNA functions through target predictionNucleic Acids Research, 2009
- MicroRNA Polymorphisms: the Future of Pharmacogenomics, Molecular Epidemiology and Individualized MedicinePharmacogenomics, 2009
- The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2Genes & Development, 2008
- A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistanceProceedings of the National Academy of Sciences, 2007
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- Human MicroRNA TargetsPLoS Biology, 2004